515 Results for "

Conformational

" in MedChemExpress (MCE) Product Catalog:
Products (515)

515 Results for "Conformational" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-102020
CAS No.: 1005504-62-0
Purity:  99.62%
Synonyms: PF-06687859
RG3039 (PF-06687859) is an orally active, blood-brain barrier-permeable DcpS inhibitor with an IC50 of 4.2 nM against hDcpS. RG3039 inhibits the decapping activity of DcpS and maintains DcpS in a catalytically inactive conformation in the central nervous system and other tissues. RG3039 extends survival and improves function in spinal muscular atrophy mice. RG3039 is applicable to research related to spinal muscular atrophy .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-110088
CAS No.: 922150-11-6
Purity:  99.73%
Target:  

MDM-2/p53

Research Areas:  

Cancer

SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-101913
CAS No.: 2205034-18-8
Purity:  99.74%
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

IL-17A antagonist 1 is an interleukin-17A (IL-17A) antagonist with an IC50 of 1.14 μM and a Kd of 0.66 μM. IL-17A antagonist 1 binds specifically and exclusively to the IL-17A homodimer at its central dimer interface pocket, induces a large conformational change that widens the pocket, and disrupts the IL-17A/IL-17RA interaction. IL-17A antagonist 1 does not bind to IL-17F or IL-17RA .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-106723A
CAS No.: 7414-56-4
Purity:  99.29%
Target:  

HSP

Research Areas:  

Cancer

AMP-PCP disodium is an ATP analogue and can bind to Hsp90 N-terminal domain with a Kd value of 3.8 μM. AMP-PCP disodium binding favors the formation of the active homodimer of Hsp90 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-123054
CAS No.: 314761-14-3
Purity:  99.49%
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

BTSA1 is a potent, high affinity and orally active BAX activator with an IC50 of 250 nM and an EC50 of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-122743
CAS No.: 247079-84-1
Purity:  99.48%
Target:  

mAChR

Research Areas:  

Neurological Disease

Iperoxo is a potent superagonist of muscarinic acetylcholine receptor (mAChR) that activates M1, M2 and M3 receptors with pEC50 of 9.87, 10.1 and 9.78. Iperoxo can be used for direct probing activation-related conformational transitions of muscarinic receptors when labeled with tritium .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-127111
CAS No.: 2375840-87-0
Purity:  99.54%
Target:  

ATP Citrate Lyase

Research Areas:  

Cancer

NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-149652
CAS No.: 689270-18-6
Purity:  99.91%
Research Areas:  

Inflammation/Immunology

IRF5-IN-1 (Compound C5) is a conformationally locked inhibitor for SLC15A4. IRF5-IN-1 blocks the downstream IRF5 activation, inhibits the TLR7/8 signaling pathway. IRF5-IN-1 exhibits anti-inflammatory responses .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144896
CAS No.: 2368903-18-6
Purity:  98.41%
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12534
CAS No.: 253449-04-6
Purity:  99.87%
Target:  

Arp2/3 Complex

Research Areas:  

Neurological Disease

Wiskostatin is a potent and selective inhibitor of neuronal Wiskott-Aldrich syndrome protein (N-WASP)-mediated actin polymerization by stabilization of the closed, autoinhibited conformation, thereby preventing Arp2/3 complex activation. Wiskostatin is also a dynamin inhibitor with an IC50 value of 20.7 μM and a potent inhibitor of clathrin-mediated endocytosis with an IC50 value of 6.9 μM. Wiskostatin causes a rapid, profound, and irreversible decrease in cellular ATP levels. Wiskostatin also induces disassembly of podosomes in a murine monocyte cell line .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16782
CAS No.: 945614-12-0
Synonyms: ARRY-614
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117163
CAS No.: 2204290-85-5
Purity:  98.93%
Target:  

Wnt β-catenin PI3K Akt c-Myc CDK

Research Areas:  

Cancer

FzM1.8 is a Wnt/β-catenin signaling pathway agonist and an allosteric agonist of Frizzled 4 (FZD4), with a pEC50 of 6.4 for FZD4 . FzM1.8 stabilizes a conformation with increased affinity for heterotrimeric G proteins, promoting Gβγ release and subsequent PI3K activation. FzM1.8 activates the AKT pathway downstream of FZD4. FzM1.8 does not affect FZD4 maturation or plasma membrane localization and does not induce FZD4 endocytosis. FzM1.8 upregulates the WNT-responsive genes C-myc and Cyclin D1, while leaving lgr5 expression unchanged. FzM1.8 can be used for colon cancer research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0735
CAS No.: 104112-82-5
Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132830
CAS No.: 1933514-13-6
Purity:  99.58%
Synonyms: KVD900
Target:  

Kallikrein

Research Areas:  

Cardiovascular Disease

Sebetralstat (KVD900) is an orally active and selective plasma kallikrein inhibitor, with an IC50 of 6.0 nM and a Ki of 3.0 nM against the human target. Sebetralstat binds to the active site of plasma kallikrein, inducing a conformational flip of Trp215 to form a U-shaped conformation; its P1 group interacts with the S1 pocket through hydrophobic interactions and displacement of high-energy water molecules, independent of the Asp189 ionic bond. Sebetralstat inhibits plasma kallikrein-kinin system activation in whole plasma, rapidly relieves laryngeal and abdominal attack symptoms of hereditary angioedema (HAE-C1INH), and reduces attack severity. Sebetralstat can be used in research related to hereditary angioedema (HAE) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W039897
CAS No.: 617-04-9
Synonyms: α-Methyl-D-mannoside
Target:  

Bacterial

Research Areas:  

Infection

Methyl α-D-mannopyranoside (α-Methyl-D-mannoside) is a methyl glycoside derivative and conformational stabilizer of α-D-mannopyranose. The glycosidic bond conformation of Methyl α-D-mannopyranoside is significantly affected by the environment. In aqueous solution, Methyl α-D-mannopyranoside stabilizes into a trans conformation via intermolecular hydrogen bonds; in the gas phase, however, steric interactions drive Methyl α-D-mannopyranoside to prefer a clockwise gauche conformation. Methyl α-D-mannopyranoside also serves as a major component of secondary cell wall polymers in some bacteria and an active precursor site for virus-targeted glycoproteins. Methyl α-D-mannopyranoside acts as an acceptor substrate for alternansucrase, mediating the transfer of D-glucopyranosyl groups to generate a variety of glycosylated oligosaccharide products, with methyl α-D-glucopyranosyl-(1→6)-α-D-mannopyranoside as the main component. Methyl α-D-mannopyranoside is applicable to studies on bacterial pathogenic mechanisms associated with mannose-specific fimbrial lectins .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W250727
CAS No.: 53313-85-2
Synonyms: 6-(p-Tolylamino)naphthalene-2-sulfonate sodium
TNS (6-(p-Tolylamino) naphthalene-2-sulfonate) sodium is a fluorescent probe used to detect the conformational state of proteins. TNS sodium binds to the central hydrophobic calyx of β-lactoglobulin (β-LG) to form a 1:1 complex, which stabilizes the folded conformation of β-LG. TNS sodium shows weak fluorescent signals in aqueous solution, but its fluorescence intensity increases significantly upon binding to the hydrophobic domains of proteins, with the maximum excitation wavelength and maximum emission wavelength located at 321 nm and 446 nm, respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-163213
CAS No.: 1352815-11-2
Research Areas:  

Others

Psoralen-triepthylene glycol azide is a compound used to probe the structure and conformation of RNA in living cells, using matching RNA crosslinking and deep sequencing or comradery methods .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-161276
CAS No.: 692774-37-1
Target:  

Apoptosis Bcl-2 Family

Research Areas:  

Cancer

BFC1108 is a small molecule Bcl-2 functional converter. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 effectively induces apoptosis in Bcl-2 expressing cancers. .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-125176
CAS No.: 2244035-16-1
Purity:  98.14%
Target:  

Bacterial

Research Areas:  

Infection

G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112273
CAS No.: 1639009-81-6
Purity:  98.78%
Target:  

Aurora Kinase

Research Areas:  

Cancer

CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer .
loading...
    loading...